Ulocuplumab

• CAT Number: I042435
• CAS Number: 1375830-34-4
• Molecular Weight: 146.2 (kDa)
• Purity: ≥95%

Ulocuplumab (Cat No.: I042435) is a human monoclonal antibody that targets CXCR4, a chemokine receptor involved in cell migration, hematopoiesis, and cancer metastasis. By blocking CXCR4, ulocuplumab disrupts its interaction with the ligand CXCL12 (SDF-1), inhibiting tumor cell homing, survival, and proliferation. It has been investigated in clinical trials for hematologic malignancies such as acute myeloid leukemia (AML) and multiple myeloma, often in combination with other therapies. Ulocuplumab shows promise as a therapeutic agent for mobilizing stem cells and combating cancer progression.

Reference

[1]. Kashyap MK, et al. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2016 Jan 19;7(3):2809-22.
[Content Brief]

[2]. Kuhne MR, et al. BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2013 Jan 15;19(2):357-66.
[Content Brief]